Collplant Biotechnologies Ltd - Asset Resilience Ratio
Collplant Biotechnologies Ltd (CLGN) has an Asset Resilience Ratio of 0.00% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2023)
This chart shows how Collplant Biotechnologies Ltd's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Collplant Biotechnologies Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Collplant Biotechnologies Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Collplant Biotechnologies Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Collplant Biotechnologies Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Collplant Biotechnologies Ltd Industry Peers by Asset Resilience Ratio
Compare Collplant Biotechnologies Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for Collplant Biotechnologies Ltd (2014–2023)
The table below shows the annual Asset Resilience Ratio data for Collplant Biotechnologies Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.71% | $241.00K | $34.13 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $37.77 Million | -- |
| 2021-12-31 | 58.86% | $30.15 Million | $51.22 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $10.84 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $9.05 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $8.07 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $3.75 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $3.47 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $4.35 Million | -- |
About Collplant Biotechnologies Ltd
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal … Read more